RhD阴性红细胞成分血制品临床需求变化与供应情况分析

张伟东 ,  梁明月 ,  姬艳丽 ,  王敏 ,  林永桔 ,  戎霞

中国输血杂志 ›› 2026, Vol. 39 ›› Issue (7) : 903 -907.

PDF (1420KB)
中国输血杂志 ›› 2026, Vol. 39 ›› Issue (7) : 903 -907. DOI: 10.13303/j.cjbt.issn.1004-549x.2026.07.013
论著

RhD阴性红细胞成分血制品临床需求变化与供应情况分析

作者信息 +

Analysis of clinical demand trends and supply status of RhD-negative red blood cell products

Author information +
文章历史 +
PDF (1454K)

摘要

目的 回顾性分析 RhD 阴性红细胞成分血的供需情况,了解 RhD 阴性红细胞制品临床需求变化和应用趋势,为优化 RhD 阴性红细胞各类制品的制备和供应提供依据。方法 在信息管理系统中统计 2021-2025 年红细胞的临床供应总量和 Rh D 阴性红细胞制品临床需求量和供应量,采用 SPSS 22. 0 统计学软件对 RhD 阴性红细胞成分血供应率和重复预约率进行趋势性 χ2 检验;并进一步分析 2025 年 RhD 阴性红细胞制品临床用血原因。结果 2021-2025 年间,RhD 阴性红细胞成分血供应率由 0. 42%(1 904. 5 U/ 448 787 U) 逐渐增加到 0. 48%(1 945 U/ 402 088. 5 U),年度间存在上升趋势(P< 0. 05);RhD 阴性红细胞实际需求量与供应量保持平衡,重复预约率由 29. 73%(804 U / 2 704 U)上升到 43. 62%(1 505 U/ 3 450 U),呈逐年上升趋势(P<0. 05);RhD 阴性新鲜红细胞制品占 RhD 阴性红细胞总供应量 87. 09%(8 270 U/ 9 495. 5 U),冰冻红细胞占 12. 91%(1 225. 5 U/ 9 495. 5 U)。 2025 年,治疗性用血占 RhD 阴性红细胞成分血总供应量的 55. 40%(1 077. 5 U/ 1 945 U),择期手术(含产科) 用血占 38. 56%(750 U/ 1 945 U),紧急用血占 6. 04%(117. 5 U/ 1 945 U)。 从血液制品种类来看,RhD 阴性冰冻红细胞在紧急用血中占比 67. 23%(79 U/ 117. 5 U),在择期手术(含产科)用血中占比 29. 47%(221 U / 750 U);新鲜 RhD 阴性红细胞悬液在治疗性用血中占比 93. 92%(1 012 U/ 1 077. 5 U),在择期手术(含产科)用血中占比 70. 56%(529 U/ 750 U);RhD 阴性洗涤红细胞和 RhD 阴性浓缩洗涤红细胞是近年来供应临床的新型制品,临床用量逐渐上升。结论 在总血液采集量下降的情况下,广州血液中心的 RhD 阴性血液保障管理体系运转良好,基本可以保障临床用血需求。 临床医院的技术发展使得 RhD 阴性浓缩洗涤红细胞应用常规化,建议对浓缩洗涤红细胞规范定义,制定相应的国家质量标准。

Abstract

Objective To retrospectively analyze the supply and demand of RhD-negative red blood cell(RBC) components, explore the dynamic changes in clinical demand and application trends of RhD-negative RBC products, and provide evidence for optimizing the preparation and supply management of various RhD-negative RBCs products. Methods The total supply of RBCs and the demand and supply of RhD-negative RBC products from 2021 to 2025 were retrieved from the information management system. The trend chi-square test was performed using SPSS 22. 0 statistical software to analyze the annual supply rate and repeat reservation rate of RhD-negative RBC products. Meanwhile, the clinical transfusion indications for RhD-negative RBC products in 2025 were further analyzed. Results From 2021 to 2025, the supply rate of RhD-negative RBC products gradually increased from 0. 42% (1 904. 5 U/ 448 787 U) to 0. 48% (1945U/ 402088. 5U), showing an upward trend across years (P<0. 05). The actual demand and supply of RhD-negative RBC products remained balanced, while the repeat reservation rate increased significantly from 29. 73% (804 U/ 2 704 U) to 43. 62% (1 505 U/ 3 450 U),showing an upward trend year by year(P<0. 05). Fresh RhD-negative RBC products accounted for 87. 09% (8 270 U/ 9 495. 5 U) of the total supply, while RhD-negative frozen RBC products accounted for 12. 91% (1 225. 5 U/ 9 495. 5 U). In 2025, therapeutic transfusion, elective surgery (including obstetric transfusion), and emergency transfusion accounted for 55. 40% (1 077. 5 U/ 1 945 U), 38. 56% (750 U/ 1 945 U), and 6. 04% (117. 5 U/ 1 945 U) of the total supply of RhD-negative RBC products, respectively. RhD-negative frozen RBC products accounted for 67. 23% (79 U/ 117. 5 U) of emergency use and 29. 47% (221 U/ 750 U) of elective surgery (including obstetrics) use;fresh RhD-negative RBC suspensions accounted for 93. 92% (1 012 U/ 1 077. 5 U) of therapeutic use and 70. 56% (529 U/ 750 U) of elective surgery (including obstetrics) use. In recent years, RhD-negative washed RBC products and concentrated washed RBC products have been introduced as new products, and their clinical utilization has shown an increasing trend. Conclusion Despite a decline in total blood collection volume, the security management system of RhD-negative RBC components in Guangzhou Blood Center has functioned largely meeting clinical demand. Advances in hospital technology had led to the routine application of RhD-negative concentrated washed RBCs. It is recommended that concentrated washed RBCs should be standardized with a formal definition and corresponding national quality standards should be established.

关键词

RhD 阴性红细胞成分血 / 临床需求 / 供应

Key words

RhD-negative red blood cell components / clinical demand / supply

引用本文

引用格式 ▾
张伟东,梁明月,姬艳丽,王敏,林永桔,戎霞. RhD阴性红细胞成分血制品临床需求变化与供应情况分析[J]. 中国输血杂志, 2026, 39(7): 903-907 DOI:10.13303/j.cjbt.issn.1004-549x.2026.07.013

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

黄小敏,姬艳丽,方群,等. 胎儿贫血行宫内输血术时 0. 7~0. 8 Hct 浓缩洗涤红细胞制备技术开发与临床应用[J].中国输血杂志,2021,34(9):1000-1002

[2]

HUANG X M, JI Y L, FANG Q, et al. Preparation and clinical application of 0. 7 ~ 0. 8 hematocrit concentrated washed red blood cells in intrauterine blood transfusion for fetal anemia[J].Chin J Blood Transfusion, 2021,34(9):1000-1002.

[3]

徐永柱,田耘博. RhD 阴性血液安全管理重庆专家共识[J].检验医学与临床,2025,22(19):2593-2598.

[4]

XU Y Z, TIAN Y B. Chongqing expert consensus on the safety management of RhD-negative blood[J].Lab Med Clin, 2025,22(19):2593-2598.

[5]

郑茵红,李阿中,李殷芳,等. 2014-2018 年浙江省 Rh 阴性血液保障情况分析[J].中华全科医学,2020,18(4):679-681.

[6]

ZHENG Y H, LI A Z, LI YF, et al. Analysis of Rh negative blood security in Zhejiang Province from 2014 to 2018[J].Chinese Journal of General Practice,2020,18(4):679-681.

[7]

李雄英,周兵,刘振北,等. 广西血站献血者 RhD 阴性稀有血型检测、资料库构建及红细胞实体库运行情况调查[J].广西医学,2023,45(9):1119-1122.

[8]

LI X Y, ZHOU B, LIU Z B, et al. Investigation on RhD-negative rare blood type screening, database construction and physical red blood cell inventory operation among blood donors in blood stations of Guangxi[J].Guangxi Medical Journal, 2023,45(9):119-1122.

[9]

CORENTIN S, MARIE P, FRANçOIS L. There is an urgent need to adopt a pull-flow logic for the supply of RBCs to meet patients′ needs:A single center study[J].Transfus Clin Biol, 2023,30(4):410-416.

[10]

张妍,马艳焱. RhD 阴性红细胞血液供应情况分析及运行模式研究[J].国际医学数据杂志,2022,6(6):147-150.

[11]

ZHANG Y, MA Y Y. Analysis of blood supply of RhD negative red blood cells and operation mode research[J].International Journal of Medicine and Date, 2022,6(6):147-150.

[12]

李双,谢毓滨. 2009-2914 年 RhD 阴性稀有血型献血者队伍建设及采供保障[J].临床输血与检验,2016,18(3):229-232.

[13]

LI S, XIE Y B. Construction of RhD-negative rare blood donor team and blood collection & supply guarantee from 2009 to 2014[J].J Clin Transfus Lab Med,2016,18(3):229-232.

[14]

吕嬿,蒋宇林,周希亚,等. 宫内输血治疗母胎 Rh 血型不合胎儿贫血 2 例[J].生殖医学杂志,2022,31(8):1137-1140.

[15]

LYU Y, JIANG Y L, ZHOU X Y, et al. Two Cases of intrauterine blood transfusion in the management of fetal anemia due to Rh alloimmunization[J].Journal of Reproductive Medicine, 2022,31(8):1137-1140.

[16]

DEVLIEGER R, VERGOTE S, VAN DEN EEDE E, et al. Intrauterine transfusion:Best practices, techniques, and evolving trends[J].Best Pract Res Clin Obstet Gynaecol, 2025,104:102686.

[17]

刘景汉,兰炯采. 临床输血学[M]. 1 版.北京:人民卫生出版社,2011,314-318.

[18]

LIU J H, LAN J C. Clinical Transfusion Medicine[M]. 1st ed. Beijing: People′ s Medical Publishing House,2011:314-318.

[19]

谭秋菊,余泽波,杨晓亮. RhD 阴性红细胞制剂的管理现状及展望[J].中国输血杂志,2020,33(7) 730-732.

[20]

TAN Q J, YU Z B, YANG X L. Current situation and prospect of the management of RhD negative RBC products[J].Chin J Blood Transfusion,2020,33(7):730-732.

基金资助

广州市医学重点学科项目(2025-2027年)

AI Summary AI Mindmap
PDF (1420KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉